American Association for Cancer Research
00085472can160543-sup-162684_1_supp_3489867_m70wgw.png (2.03 MB)

Supplementary Figure 4 from αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor

Download (2.03 MB)
posted on 2023-03-31, 00:24 authored by Huimin Lu, Tao Wang, Jing Li, Carmine Fedele, Qin Liu, Jianzhong Zhang, Zhong Jiang, Dhanpat Jain, Renato V. Iozzo, Shelia M. Violette, Paul H. Weinreb, Roger J. Davis, Daniel Gioeli, Thomas J. FitzGerald, Dario C. Altieri, Lucia R. Languino

Full-size scans of PSA and androgen receptor immunoblots shown in Figure 4.



Prostate Cancer Foundation

Danny Cancer Funds

Postdoctoral Research Fellowship from the American Italian Cancer Foundation



Androgen receptor signaling fuels prostate cancer and is a major therapeutic target. However, mechanisms of resistance to therapeutic androgen ablation are not well understood. Here, using a prostate cancer mouse model, Ptenpc−/−, carrying a prostate epithelial-specific Pten deletion, we show that the αvβ6 integrin is required for tumor growth in vivo of castrated as well as of noncastrated mice. We describe a novel signaling pathway that couples the αvβ6 integrin cell surface receptor to androgen receptor via activation of JNK1 and causes increased nuclear localization and activity of androgen receptor. This downstream kinase activation by αvβ6 is specific for JNK1, with no involvement of p38 or ERK kinase. In addition, differential phosphorylation of Akt is not observed under these conditions, nor is cell morphology affected by αvβ6 expression. This pathway, which is specific for αvβ6, because it is not regulated by a different αv-containing integrin, αvβ3, promotes upregulation of survivin, which in turn supports anchorage-independent growth of αvβ6-expressing cells. Consistently, both αvβ6 and survivin are significantly increased in prostatic adenocarcinoma, but are not detected in normal prostatic epithelium. Neither XIAP nor Bcl-2 is affected by αvβ6 expression. In conclusion, we show that αvβ6 expression is required for prostate cancer progression, including castrate-resistant prostate cancer; mechanistically, by promoting activation of JNK1, the αvβ6 integrin causes androgen receptor–increased activity in the absence of androgen and consequent upregulation of survivin. These preclinical results pave the way for further clinical development of αvβ6 antagonists for prostate cancer therapy. Cancer Res; 76(17); 5163–74. ©2016 AACR.

Usage metrics

    Cancer Research



    Ref. manager